FTC says Martin Shkreli 'flagrantly and repeatedly' violated his lifetime pharma banBusiness Insider • 10/13/26
These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise24/7 Wall Street • 10/13/26
Enodia Therapeutics Announces Research Collaboration and License Agreement with Pfizer to Develop Sec61-Targeting Small MoleculesBusiness Wire • 10/13/26
Johnson & Johnson vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/12/26
Pfizer Moves Past 50-Day SMA: Time to Buy, Hold or Exit the Stock?Zacks Investment Research • 10/12/26
These 4 Dividend Stocks Offer Tempting Yields. But the Warning Signs Are Getting Harder to Ignore24/7 Wall Street • 10/11/26
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up24/7 Wall Street • 10/09/26
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to KnowZacks Investment Research • 10/09/26
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks24/7 Wall Street • 10/09/26
Pfizer: Previously Bearish, I'm Converting To A Cautious Bull (Rating Upgrade)Seeking Alpha • 10/09/26
Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool • 10/09/26
Pfizer's Oncology Outlook: Key Drivers to Watch Ahead of Q3 ResultsZacks Investment Research • 10/08/26
Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/08/26
FDA Backs PFE's Tukysa Combo in Front-Line Maintenance Breast CancerZacks Investment Research • 10/08/26
Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next.The Motley Fool • 10/08/26
Pfizer's Yield Is Three Times Bigger. Johnson & Johnson's Dividend Has Something Pfizer Does Not24/7 Wall Street • 10/08/26